Connective tissue remodelling: Cross-talk between endothelins and matrix metalloproteinases

Current Vascular Pharmacology

Volumn 3, Issue 4, 2005, Pages 369-379

  Abraham, David ^a   Ponticos, Markella ^a   Nagase, Hideaki ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Connective tissue remodelling; Endothelin; Extracellular matrix; Fibrosis; Matrix metalloproteinases; Scarring; Tissue inhibitors of metalloproteinases

Indexed keywords

BOSENTAN; CHEMOKINE; CRE RECOMBINASE; CYTOKINE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN RECEPTOR; GELATINASE A; GELATINASE B; GROWTH FACTOR; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

BREAST CANCER; CANCER CELL CULTURE; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL TYPE; CONNECTIVE TISSUE; CONNECTIVE TISSUE CELL; CORONARY ARTERY LIGATION; CRANIOFACIAL MALFORMATION; DEATH; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; GENE DELETION; GENE OVEREXPRESSION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; KAPOSI SARCOMA; KIDNEY FIBROSIS; LUNG DISEASE; LUNG FIBROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MELANOMA; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OSTEOARTHRITIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; RAT; RECEPTOR BINDING; RESPIRATORY FAILURE; REVIEW; SYSTEMIC SCLEROSIS; TISSUE INJURY; TISSUE REPAIR; TRANSGENIC ANIMAL; VASOCONSTRICTION; ANIMAL; ENZYMOLOGY; METABOLISM; PHYSIOLOGY; REGENERATION; SIGNAL TRANSDUCTION;

ANIMALS; CONNECTIVE TISSUE; ENDOTHELINS; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASES; RECEPTORS, ENDOTHELIN; REGENERATION; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 24644489710     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016105774329480     Document Type: Review

References (97)

1. Nagase H, and Woessner, JF, Jr.: Matrix metalloproteinases. J. Biol Chem 1999, 274: 21491-21494.
2. Roy-Beaudry M, Martel-Pelletier J, Pelletier JP, M'Barek KN, Christgau S, Shipkolye F et al.: Endothelin 1 promotes osteoarthritic cartilage degradation via matrix metalloprotease 1 and matrix metalloprotease 13 induction. Arthritis Rheum 2003, 48: 2855-2864.
3. Grimshaw MJ: Endothelins in breast tumour cell invasion. Cancer Lett 2005, 222: 129-138.
4. Ihling C, Bohrmann B, Schaefer HE, Technau-Ihling K, Loeffler BM: Endothelin-1 and endothelin converting enzyme-1 in human atherosclerosis - novel targets for pharmacotherapy in atherosclerosis. Curr Vasc Pharmacol 2004, 2: 249-258.
5. Ihling C, Szombathy T, Bohrmann B, Brockhaus M, Schaefer HE, Loeffler BM: Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation 2001, 104: 864-869.
6. Pepke-Zaba J, Morrell NW: The endothelin system and its role in pulmonary arterial hypertension (PAH). Thorax 2005, 60: 443-444.
7. Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM: Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 1998, 31 Suppl 1: S360-S363.
8. Xu SW, Denton CP, Dashwood MR, Abraham DJ, Black CM: Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol 1998, 31 Suppl 1: S545-S547.
9. Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T: A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens Suppl 1998, 6: S188-S191.
10. Yu JC, Pickard JD, Davenport AP: Endothelin ETA receptor expression in human cerebrovascular smooth muscle cells. Br J Pharmacol 1995, 116: 2441-2446.
11. Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD et al.: Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001, 116: 417-425.
12. Yoshimura A, Iwasaki S, Inui K, Ideura T, Koshikawa S, Yanagisawa M, et al.: Endothelin-1 and endothelin B type receptor are induced in mesangial proliferative nephritis in the rat. Kidney Int 1995, 48: 1290-1297.
13. Rubanyi GM, Polokoff MA: Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994, 46: 325-415.
14. Levin ER: Endothelins. N Engl J Med 1995, 333: 356-363.
15. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, Dewit D, et al.: ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994, 78: 473-485.
16. Emoto N, Yanagisawa M: Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 1995, 270: 15262-15268.
17. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, et al.: A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003, 9: 407-415.
18. Barnes K, Turner AJ: The endothelin system and endothelin-converting enzyme in the brain: molecular and cellular studies. Neurochem Res 1997, 22: 1033-1040.
19. The Endothelin System in Cardiopulmonary Diseases, 1st edn. Friedrich Reinhardt Verlag; 2003. Editors Clozel M and Rubin LJ.
20. Gregan B, Jurgensen J, Papsdorf G, Furkert J, Schaefer M, Beyermann M, et al.: Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem 2004, 279: 27679-27687.
21. Mayes MD: Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003, 48: 1190-1199.
22. Shi-Wen X, Howat SL, Renzoni EA, Holmes A, Pearson JD, Dashwood MR, et al.: Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J Biol Chem 2004.
23. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G et al.: Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004, 15: 2707-2719.
24. Attina T, Camidge R, Newby DE, Webb DJ: Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart 2005, 91: 825-831.
25. Clozel M, Salloukh H: Role of endothelin in fibrosis and antifibrotic potential of bosentan. Ann Med 2005, 37: 2-12.
26. Russell FD, Davenport AP: Secretory pathways in endothelin synthesis. Br J Pharmacol 1999, 126: 391-398.
27. Russell FD, Skepper JN, Davenport AP: Evidence using immunoelectron microscopy for regulated and constitutive pathways in the transport and release of endothelin. J Cardiovasc Pharmacol 1998, 31: 424-430.
28. Matsui K, Takano Y, Yu ZX, Hi JE, Stetler-Stevenson WG, Travis WD et al.: Immunohistochemical study of endothelin-1 and matrix metalloproteinases in plexogenic pulmonary arteriopathy. Pathol Res Pract 2002, 198: 403-412.
29. Fraccarollo D, Galuppo P, Bauersachs J, Ertl G: Collagen accumulation after myocardial infarction: effects of ETA receptor blockade and implications for early remodeling. Cardiovasc Res 2002, 54: 559-567.
30. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, et al.: TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003, 114: 171-180.
31. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92: 827-839.
32. Yu WH, Woessner JF, Jr.: Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7). J Biol Chem 2000, 275: 4183-4191.
33. Pilcher BK, Dumin JA, Sudbeck BD, Krane SM, Welgus HG, Parks WC: The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J Cell Biol 1997, 137: 1445-1457.
34. Holliday LS, Welgus HG, Fliszar CJ, Veith GM, Jeffrey JJ, Gluck SL: Initiation of osteoclast bone resorption by interstitial collagenase. J Biol Chem 1997, 272: 22053-22058.
35. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V: Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997, 277: 225-228.
36. Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V: Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 2000, 148: 615-624.
37. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y: Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J 1997, 322 (Pt 3): 809-814.
38. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA: The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 1996, 271: 10079-10086.
39. Overall CM, McQuibban GA, Clark-Lewis I: Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics. Biol Chem 2002, 383: 1059-1066.
40. Kadri Z, Petitfrere E, Boudot C, Freyssinier JM, Fichelson S, Mayeux P, et al.: Erythropoietin induction of tissue inhibitors of metalloproteinase-1 expression and secretion is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways. Cell Growth Differ 2000, 11: 573-580.
41. Fernandez-Patron C, Radomski MW, Davidge ST: Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999, 85: 906-911.
42. Yu Q, Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14: 163-176.
43. Shi-Wen X, Howat SL, Renzoni EA, Holmes A, Pearson JD, Dashwood MR, et al.: Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J Biol Chem 2004, ..
44. Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT: Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993, 27: 2130-2134.
45. Kitamura A, Kagami S, Urushihara M, Kondo S, Yoshizumi M, Tamaki T, et al.: Endothelin-1 is a potent stimulator of alpha1beta1 integrin-mediated collagen matrix remodeling by rat mesangial cells. Biochem Biophys Res Commun 2002, 299: 555-561.
46. Yao J, Morioka T, Li B, Oite T: Endothelin is a potent inhibitor of matrix metalloproteinase-2 secretion and activation in rat mesangial cells. Am J Physiol Renal Physiol 2001, 280: F628-F635.
47. Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000, 1477: 267-283.
48. Baker AH, Edwards DR, Murphy G: Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002, 115: 3719-3727.
49. Murphy G, Houbrechts A, Cockett MI, Williamson RA, O'Shea M, Docherty AJ: The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 1991, 30: 8097-8102.
50. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995, 270: 5331-5338.
51. IMP-3Replace this as indicated for TIMP-3 paper. Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, van Westrum SS, et al.: The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 1998, 273: 871-880.
52. Butler GS, Hutton M, Wattam BA, Williamson RA, Knauper V, Willenbrock F, et al.: The specificity of TIMP-2 for matrix metalloproteinases can be modified by single amino acid mutations. J Biol Chem 1999, 274: 20391-20396.
53. Bigg HF, Shi YE, Liu YE, Steffensen B, Overall CM: Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2. J Biol Chem 1997, 272: 15496-15500.
54. Lambert E, Dasse E, Haye B, Petitfrere E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004, 49: 187-198.
55. Rockey DC: Vascular mediators in the injured liver. Hepatology 2003, 37: 4-12.
56. Fernandez-Patron C, Radomski MW, Davidge ST: Role of matrix metalloproteinase-2 in thrombin-induced vasorelaxation of rat mesenteric arteries. Am J Physiol Heart Circ Physiol 2000, 278: H1473-H1479.
57. Cao J, Drews M, Lee HM, Conner C, Bahou WF, Zucker S: The 9-kDa N-terminal propeptide domain of MT1-MMP is required for the activation of progelatinase A. Ann N Y Acad Sci 1999, 878: 710-712.
58. Lafleur MA, Hollenberg MD, Atkinson SJ, Knauper V, Murphy G, Edwards DR: Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. Biochem J 2001, 357: 107-115.
59. Jeyabalan A, Novak J, Danielson LA, Kerchner LJ, Opett SL, Conrad KP: Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. Circ Res 2003, 93: 1249-1257.
60. Fernandez-Patron C, Zouki C, Whittal R, Chan JS, Davidge ST, Filep JG: Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1[1-32]. FASEB J 2001, 15: 2230-2240.
61. Fraccarollo D, Bauersachs J, Kellner M, Galuppo P, Ertl G: Cardioprotection by long-term ET(A) receptor blockade and ACE inhibition in rats with congestive heart failure: mono- versus combination therapy. Cardiovasc Res 2002, 54: 85-94.
62. Ergul A, Portik-Dobos V, Giulumian AD, Molero MM, Fuchs LC: Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation. Am J Physiol Heart Circ Physiol 2003, 285: H2225-H2232.
63. Murray DB, Gardner JD, Brower GL, Janicki JS: Endothelin-1 mediates cardiac mast cell degranulation, matrix metalloproteinase activation, and myocardial remodeling in rats. Am J Physiol Heart Circ Physiol 2004, 287: H2295-H2299.
64. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, et al.: Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/PI3 kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004, ..
65. Bagnato A, Rosano L, Di C, V, Albini A, Salani D, Varmi M, et al.: Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells. Am J Pathol 2001, 158: 841-847.
66. Rosano L, Spinella F, Di C, V, Nicotra MR, Albini A, Natali PG, et al.: Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo. Am J Pathol 2003, 163: 753-762.
67. Tsuruda T, Jougasaki M, Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lee SC, et al.: Ventricular adrenomedullin is associated with myocyte hypertrophy in human transplanted heart. Regul Pept 2003, 112: 161-166.
68. Tsuruda T, Kato J, Cao YN, Hatakeyama K, Masuyama H, Imamura T, et al.: Adrenomedullin induces matrix metalloproteinase-2 activity in rat aortic adventitial fibroblasts. Biochem Biophys Res Commun 2004, 325: 80-84.
69. Manacu CA, Martel-Pelletier J, Roy-Beaudry M, Pelletier JP, Fernandes JC, Shipkolye FS, et al.: Endothelin-1 in osteoarthritic chondrocytes triggers nitric oxide production and upregulates collagenase production. Arthritis Res Ther 2005, 7: R324-R332.
70. Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD, et al.: Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001, 116: 417-425.
71. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, et al.: Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994, 368: 703-710.
72. Kurihara Y, Kurihara H, Oda H, Maemura K, Nagai R, Ishikawa T, et al.: Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. J Clin Invest 1995, 96: 293-300.
73. Shohet RV, Kisanuki YY, Zhao XS, Siddiquee Z, Franco F, Yanagisawa M: Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. Proc Natl Acad Sci USA 2004, 101: 2088-2093.
74. Clouthier DE, Hosoda K, Richardson JA, Williams SC, Yanagisawa H, Kuwaki T, et al. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 1998, 125: 813-824.
75. Berthiaume N, Yanagisawa M, D'Orleans-Juste P: Contribution of endogenous endothelin-1 and endothelin-A-receptors to the hypertensive state of endothelin-B heterozygous (+/-) knockout mice. J Cardiovasc Pharmacol 2000, 36: S72-S74.
76. Berthiaume N, Yanagisawa M, Labonte J, D'Orleans-Juste P: Heterozygous knock-Out of ET(B) receptors induces BQ-123-sensitive hypertension in the mouse. Hypertension 2000, 36: 1002-1007.
77. Won KJ, Torihashi S, Mitsui-Saito M, Hori M, Sato K, Suzuki T, et al.: Increased smooth muscle contractility of intestine in the genetic null of the endothelin ETB receptor: a rat model for long segment Hirschsprung's disease. Gut 2002, 50: 355-360.
78. Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC, Takeda S, et al.: Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest 2000, 105: 1373-1382.
79. Yanagisawa H, Hammer RE, Richardson JA, Williams SC, Clouthier DE, Yanagisawa M: Role of Endothelin-1/Endothelin-A receptor-mediated signaling pathway in the aortic arch patterning in mice. J Clin Invest 1998, 102: 22-33.
80. Gariepy CE, Williams SC, Richardson JA, Hammer RE, Yanagisawa M: Transgenic expression of the endothelin-B receptor prevents congenital intestinal aganglionosis in a rat model of Hirschsprung disease. J Clin Invest 1998, 102: 1092-1101.
81. Hocher B, Schwarz A, Fagan KA, Thone-Reineke C, El Hag K, Kusserow H, et al.: Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 2000, 23: 19-26.
82. Hocher B, Paul M: Transgenic animal models for the analysis of the renal endothelin system. Nephrol Dial Transplant 2000, 15: 935-937.
83. Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, et al.: Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997, 99: 1380-1389.
84. Quaschning T, Rebhan B, Wunderlich C, Wanner C, Richter CM, Pfab T, et al.: Endothelin B receptor-deficient mice develop endothelial dysfunction independently of salt loading. J Hypertens 2005, 23: 979-985.
85. Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C: Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 2001, 37: 490-496.
86. Dussaule JC, Tharaux PL, Boffa JJ, Fakhouri F, Ardaillou R, Chatziantoniou C: Mechanisms mediating the renal profibrotic actions of vasoactive peptides in transgenic mice. J Am Soc Nephrol 2000, 11 Suppl 16: S124-S128.
87. Dussaule JC, Boffa JJ, Tharaux PL, Fakhouri F, Ardaillou R, Chatziantoniou C: Endothelin, renal diseases, and hypertension. Adv Nephrol Necker Hosp 2000, 30: 281-303.
88. Nakamura T, Ebihara I, Fukui M, Osada S, Tomino Y, Masaki T, et al.: Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB/W F1 mice. Ren Physiol Biochem 1993, 16: 233-243.
89. Vieillard-Baron A, Frisdal E, Raffestin B, Baker AH, Eddahibi S, Adnot S et al.: Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer limits monocrotaline-induced pulmonary vascular remodeling in rats. Hum Gene Ther 2003, 14: 861-869.
90. Hill NS, Warburton RR, Pietras L, Klinger JR: Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol 1997, 83: 1209-1215.
91. Cho JJ, Hocher B, Herbst H, Jia JD, Ruehl M, Hahn EG, et al.: An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 2000, 118: 1169-1178.
92. Porter S, Edwards D, et al. Biochem J 2005, review.
93. Mishra R, Leahy P, Simonson MS: Gene expression profile of endothelin-1-induced growth in glomerular mesangial cells. Am J Physiol Cell Physiol 2003, 285: C1109-C1115.
94. Predic J, Soskic V, Bradley D, Godovac-Zimmermann J: Monitoring of gene expression by functional proteomics: response of human lung fibroblast cells to stimulation by endothelin-1. Biochemistry 2002, 41: 1070-1078.
95. von Schroeder HP, Veillette CJ, Payandeh J, Qureshi A, Heersche JN: Endothelin-1 promotes osteoprogenitor proliferation and differentiation in fetal rat calvarial cell cultures. Bone 2003, 33: 673-684.
96. Bridges LC, Bowditch RD: ADAM-Integrin Interactions: potential integrin regulated ectodomain shedding activity. Curr Pharm Des 2005, 11: 837-847.
97. Apte SS: A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. Int J Biochem Cell Biol 2004, 36: 981-985.